Related Experiment Video
Updated: Jun 20, 2026
08:37
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
4-1BB as a therapeutic target for human disease
1Molecular Immunology, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, California, 92037, USA.
Advances in Experimental Medicine and Biology
|September 18, 2009
Summary
4-1BB (CD137) agonistic antibody therapy shows promise for treating immune diseases like cancer and asthma. This review explores 4-1BB
Area of Science:
- Immunology and immunotherapy research.
- Exploration of immune system modulation.
Background:
- 4-1BB (CD137) is a target of interest for immunotherapy.
- Positive results observed in preclinical models for various diseases.
Purpose of the Study:
- To review basic research on 4-1BB.
- To summarize findings on 4-1BB immunotherapy.
- To offer mechanistic insights into 4-1BB functions.
Main Methods:
- Literature review of basic research.
- Analysis of immunotherapy studies in disease models.
- Examination of stimulatory and regulatory functions.
Main Results:
- 4-1BB agonistic antibody treatment shows efficacy in mouse models.
- Potential applications in cancer, autoimmune diseases, and asthma.
- 4-1BB influences both stimulatory and regulatory immune responses.
Conclusions:
- 4-1BB is a promising target for immunotherapy across diverse immune conditions.
- Further research into 4-1BB's mechanisms can optimize therapeutic strategies.
- Preclinical data supports the broad potential of 4-1BB-targeted therapies.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...